John Wahren
Chief Tech/Sci/R&D Officer at Creative Peptides Sweden AB
John Wahren active positions
| Companies | Position | Start | End |
|---|---|---|---|
Creative Peptides Sweden AB
 Creative Peptides Sweden AB Pharmaceuticals: MajorHealth Technology Creative Peptides Sweden AB develops and manufactures drugs. The company discovers and develops biopharmaceutical drugs to treat complications of Type 1 diabetes. It was founded in 1996 and is headquartered in Stockholm, Sweden. | Chief Tech/Sci/R&D Officer | - | - |
| Karolinska Institutet | Corporate Officer/Principal | 24/06/2009 | - |
Career history of John Wahren
Former positions of John Wahren
| Companies | Position | Start | End |
|---|---|---|---|
| University of Lausanne | Corporate Officer/Principal | 01/01/1984 | 01/01/1984 |
Cebix, Inc.
 Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Director/Board Member | 24/06/2009 | - |
| Chief Tech/Sci/R&D Officer | 24/06/2009 | - | |
| Founder | 13/04/2010 | - |
Training of John Wahren
| Karolinska Institutet | Doctorate Degree |
Statistics
International
| Sweden | 3 |
| United States | 2 |
| Switzerland | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Creative Peptides Sweden AB
Creative Peptides Sweden AB Pharmaceuticals: MajorHealth Technology Creative Peptides Sweden AB develops and manufactures drugs. The company discovers and develops biopharmaceutical drugs to treat complications of Type 1 diabetes. It was founded in 1996 and is headquartered in Stockholm, Sweden. | Health Technology |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- John Wahren
- Experience
